Price targets show what analysts believes a stock will be worth at the end of a certain time period. Accern also assigned headlines about the biotechnology company an impact score of 44.7501761026553 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. The Return on Investment (ROI) ratio of Nabriva Therapeutics AG (NBRV) is -70.3 percent. The rating was maintained by Cantor Fitzgerald on Thursday, June 22 with "Buy". Equity analyst SunTrust Robinson Humphrey added NBRV to its research portfolio with a rating of "Buy". The stock of Nabriva Therapeutics plc - Ordinary Shares (NASDAQ:NBRV) earned "Buy" rating by H.C. Wainwright on Thursday, September 8. H.C. Wainwright has "Buy" rating and $18 target. Cantor Fitzgerald maintained Nabriva Therapeutics plc - Ordinary Shares (NASDAQ:NBRV) rating on Monday, June 5.
Nabriva Therapeutics plc (NBRV) saw -14.35 million in free cash flow last quarter, representing a quarterly net change in cash of -5.47 million. The firm has "Outperform" rating given on Tuesday, October 13 by RBC Capital Markets. The share price has moved backward from its 20 days moving average, trading at a distance of -3.29% and stays -12.7% away from its 50 days moving average. On average, analysts expect that Nabriva Therapeutics AG will post ($2.29) earnings per share for the current year.
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.93 in total earnings per share. Analysts have a mean recommendation of 1.70 on this stock. After having $-0.54 EPS previously, Nabriva Therapeutics plc - Ordinary Shares's analysts see 3.70 % EPS growth.
COPYRIGHT VIOLATION NOTICE: "Cantor Fitzgerald Reiterates "Buy" Rating for Nabriva Therapeutics AG (NBRV)" was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another site, it was copied illegally and republished in violation of US and global copyright laws.
Analysts await Nabriva Therapeutics plc - Ordinary Shares (NASDAQ:NBRV) to report earnings on November, 15.
In other news, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the company's stock in a transaction that occurred on Monday, September 18th.
As of the end of the quarter Tower Research Capital LLC (trc) had acquired a total of 409 shares growing its stake by 435.1%. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.75% of the company's stock. The disclosure for this purchase can be found here. Shares were disposed in a price range of $10.94, amounting to $143,609.38. after the transaction, the executive now has 2,583,229 company stock worth at $28,260,525.26. executive have unloaded a total of 279,000 stocks of company shares worth at $2,870,869 during the last 90 days.
Institutional investors have recently bought and sold shares of the company. Nabriva Therapeutics AG was incorporated in 2005 and is headquartered in Vienna, Austria. As of quarter end Hillhouse Capital Management, Ltd. had sold 500 shares trimming its position 0.1%. Nationwide Fund Advisors bought a new position in shares of Nabriva Therapeutics AG in the first quarter worth $2,074,000. Executives own 2.75% of the firms stock. All of the ordinary shares in the offering are to be sold by Nabriva Therapeutics. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company's medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.